Flexion Therapeutics (NASDAQ:FLXN) issued its earnings results on Thursday. The specialty pharmaceutical company reported ($1.00) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.01) by $0.01, Fidelity Earnings reports. Flexion Therapeutics had a negative return on equity of 175.29% and a negative net margin of 368.31%. The firm had revenue of $21.79 million for the quarter, compared to analysts’ expectations of $18.85 million.
FLXN traded down $0.69 during midday trading on Friday, reaching $16.43. 1,132,400 shares of the company were exchanged, compared to its average volume of 622,178. The stock’s 50-day simple moving average is $14.85 and its 200 day simple moving average is $12.36. The stock has a market capitalization of $655.05 million, a P/E ratio of -3.66 and a beta of 1.38. The company has a debt-to-equity ratio of 3.95, a quick ratio of 7.33 and a current ratio of 7.80. Flexion Therapeutics has a one year low of $8.76 and a one year high of $17.82.
A number of brokerages have issued reports on FLXN. ValuEngine cut Flexion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, October 25th. Northland Securities set a $20.00 target price on Flexion Therapeutics and gave the stock a “buy” rating in a report on Tuesday, September 10th. BidaskClub upgraded Flexion Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, November 5th. Finally, Zacks Investment Research cut Flexion Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 8th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Flexion Therapeutics has an average rating of “Buy” and a consensus target price of $23.57.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.
Featured Article: What is the Gross Domestic Product (GDP)?
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.